APA (7th ed.) Citation

(2021). Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.

Chicago Style (17th ed.) Citation

Efficacy of Osimertinib Plus Bevacizumab in Glioblastoma Patients with Simultaneous EGFR Amplification and EGFRvIII Mutation. 2021.

MLA (8th ed.) Citation

Efficacy of Osimertinib Plus Bevacizumab in Glioblastoma Patients with Simultaneous EGFR Amplification and EGFRvIII Mutation. 2021.

Warning: These citations may not always be 100% accurate.